Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

"intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of ongoing discussions with regulatory authorities and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential inability to reach final agreement with regulatory agencies on the lifting of the clinical hold on the AT2220 program; the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. Additionally, with respect to statements regarding projections of the Company's cash position and expected use of cash during 2009, actual results may differ based on market factors, the company's ability to execute its operational and budget plans, and its achievement of milest
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... laureate Herbert Kroemer famously observed, referring to the ... where layers of different materials meet. In today,s ... of metal oxides are becoming increasingly prominent, with ... superconductors, ferroelectrics and multiferroics. Realizing the vast potential ...
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused ... analysis of tumor cells in the bloodstream, today announced ... decision support application powered by CollabRx, Inc. , ... test, Therapy Finder will provide breast cancer patients and ...
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
Breaking Biology Technology:A deeper look at interfaces 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... Alberta Centre for Advanced,MNT (Microsystems and Nanotechnology) Products ... Yallup as Chief Technology Officer. In this new,role ... within ACAMP to,build a world-class capability in Alberta ... technology devices, turning them into market-ready,commercial or industrial ...
... are not risk takers with their health, yet up to ... screenings,- 42 percent are at elevated risk for cardiovascular events, yet 20 percent, ... ... MORRISTOWN, N.J., Sept. 22 A new survey of men and,women age 40 ...
... F. Finn, Jr.,C.P.A. ("Finn"), Assignee of the assets of ... that all oral drug delivery,intellectual property will be sold ... The three presentations were:, 1. BIOROD -- ... Affecting the Bioadhesion Performance of,Spheromer III, 3. Pharmacokinetics ...
Cached Biology Technology:Chief Technology Officer Joins ACAMP 2Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 2Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 3Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 4Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 5Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 6Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 7Spherics, Inc. Presented Three Key Technologies (BIOROD(TM), BIOGIT(TM), and SPHEROMER(TM)) at the 35th Annual Meeting of Controlled Release Society 2
(Date:4/20/2014)... corn crop residue to make ethanol and other biofuels ... than gasoline, according to a study published today in ... findings by a University of Nebraska-Lincoln team of researchers ... to meet federal mandates to ramp up ethanol production ... the stalks, leaves and cobs in cornfields after harvest ...
(Date:4/18/2014)... while feeding a world population predicted to reach ... approach to conservation that considers human-altered landscapes such ... and the natural habitat that supports it might ... where at least three-quarters of the land surface ... is vulnerable to human-caused impacts such as climate ...
(Date:4/18/2014)... soon as they,re planted may be good news for a ... the wild, a plant whose seeds sprouted at the first ... just an insurance policy against late frosts or unexpected dry ... too: Plants whose seeds put off sprouting until conditions ... a team of researchers working at the National Evolutionary Synthesis ...
Breaking Biology News(10 mins):Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Plants with dormant seeds give rise to more species 2
... thrills among fossil collectors than a complete trilobite. These ... went extinct more than 250 million years ago, ... rare instances, an entire population of trilobites is found ... environment and behavior in these mass graves. Brett, ...
... the mechanical strength of cancer cell mucus layers provides ... suggests why some cancer cells are more resistant to ... of engineering at Northeastern University, Boston, Mass. ... protect against infection. Cancer cells, however, produce far more ...
... release is available in Spanish . ... growers find a replacement for methyl bromide are studying an ... ingredients. Researchers with USDA,s Agricultural Research Service (ARS) are ... microbial activity could be used to replace the popular fumigant. ...
Cached Biology News:Fossils record ancient migrations and trilobite orgies 2Breaking the mucus barrier unveils cancer cell secrets 2Alternatives eyed for methyl bromide 2
... cocktail of 3 siRNAs specifically targeted to ... popular product. The siTrio reagent guarantees you ... target gene when used under standard conditions ... of optimal transfection with one of B-Bridges ...
... Corticosterone kit is a competitive enzymeimmunoassay (EIA) ... mouse or rat serum or plasma. Corticosterone ... in rats and mice, and in most ... reptiles. Most mammals produce both corticosterone and ...
... This is a molecular screening, low melting ... molecular sieving. It is recommended for separation ... size such as PCR products. Micro ABgarose ... is not recommended for blotting techniques. At ...
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
Biology Products: